tiprankstipranks
Revance announces commercial launch of DAXXIFY
PremiumThe FlyRevance announces commercial launch of DAXXIFY
12d ago
Revance affirms 2024 revenue outlook of at least $280M, consensus $281.72M
PremiumThe Fly
Revance affirms 2024 revenue outlook of at least $280M, consensus $281.72M
12d ago
Revance reports Q1 EPS (54c), consensus (75c)
PremiumThe Fly
Revance reports Q1 EPS (54c), consensus (75c)
12d ago
Revance price target raised to $9 from $8 at Goldman Sachs
PremiumThe FlyRevance price target raised to $9 from $8 at Goldman Sachs
3M ago
Revance price target lowered to $20 from $42 at Piper Sandler
PremiumThe Fly
Revance price target lowered to $20 from $42 at Piper Sandler
3M ago
Revance Therapeutics Renews Manufacturing Deal and Announces Executive Transition
PremiumCompany Announcements
Revance Therapeutics Renews Manufacturing Deal and Announces Executive Transition
3M ago
Revance Therapeutics Sets 2024 Goals, Updates Executive Severance Plan
PremiumCompany AnnouncementsRevance Therapeutics Sets 2024 Goals, Updates Executive Severance Plan
3M ago
Revance Therapeutics Sets Executive Compensation for 2024
PremiumCompany Announcements
Revance Therapeutics Sets Executive Compensation for 2024
3M ago
Revance announces CMS assigns permanent J-code for Daxxify
PremiumThe Fly
Revance announces CMS assigns permanent J-code for Daxxify
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100